New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
11:58 EDTIPXL, HAS, GNK, BKDHigh option volume stocks: GNK, RKT, IPXL, BKD, HAS
News For GNK;IPXL;BKD;HAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:00 EDTIPXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:58 EDTIPXLImpax downgraded to Sell from Neutral at UBS
UBS downgraded Impax Laboratories to Sell saying the risk/reward is biased to the downside following the recent rally in shares. UBS attributes the recent run-up in shares to expectations the company will do more deals or get acquired. The firm does not see either scenario driving the stock much above current levels "any time soon." It keeps a $36 price target for Impax shares.
April 8, 2015
14:54 EDTBKDBrookdale Senior Living considering sale of real estate, says dealReporter
Subscribe for More Information
10:01 EDTIPXLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
April 7, 2015
16:11 EDTIPXLImpax initiated with a Hold at Deutsche Bank
Subscribe for More Information
10:19 EDTBKDHigh option volume stocks
Subscribe for More Information
07:29 EDTHASMKM Partners loweres Hasbro estimates on FX and port issues
MKM Partners lowered Hasbro Q1 estimates due to FX headwinds and West Coast port issues that have resulted in retailers stocking less inventory. The firm remains concerned consensus FY15 estimates remain too high and maintains its Neutral rating and $55 price target.
06:43 EDTIPXLImpax price target raised to $58 from $49 at Piper Jaffray
Piper Jaffray raised its price target for Impax Laboratories to $58 saying retail prescription data shows the company's generics business is "quietly performing well." Piper believes revenue from the generics segment could outperform its expectations for 2015 and also drive "significant"growth longer-term. It reiterates an Overweight rating on Impax.
April 6, 2015
07:09 EDTIPXLImpax price target raised to $56 from $48 at JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use